The neuroimaging group, consisting of Artinis and NIRx, leading in functional Near-Infrared Spectroscopy (fNIRS) solutions, has appointed Matthew Stork as Chief Executive Officer (CEO) and Maarten Jaspers as Finance Director.
Matthew Stork has over 25 years’ executive leadership experience in the international MedTech sector and brings extensive organizational and strategic leadership expertise. Before joining the group, Matthew held management positions with several international neuroscience technology and medical imaging corporations, including GE Healthcare. He has a clinical background and a PhD in AI in medicine.
Maarten Jaspers, who is a Chartered Accountant, has over 15 years’ experience and has strong knowledge in financial management and structuring. Before joining the group, Maarten held senior financial roles for various corporations across multiple sectors.
The appointment of these two Directors is an important milestone. It strengthens the group’s highly capable management team with further experience in driving strategic business growth and helps to build a strong basis for it to further expand its position as a leading developer of neuroimaging technologies. Matthew and Maarten will join the group’s existing leadership team, supporting both Artinis and NIRx, as well as future acquisitions.
Today, Artinis and NIRx have around 130 people across three locations in Germany, the Netherlands and the United States. The group benefits from leveraging the companies’ complementary product offerings, shared expertise, integrated R&D, and increased scale, which together accelerate innovation and commercial growth. The group combines strong growth opportunities with an attractive potential for other companies looking for partnership to strengthen their competitive position in the global neuroscience tools market.
Matthew Stork, CEO of Artinis and NIRx, commented: “I am delighted to join the group and to work alongside the talented teams at Artinis and NIRx. Together, we will build on the group’s strong scientific and commercial foundations to support long-term growth and innovation in neuroimaging.”
Maarten Jaspers, Finance Director of Artinis and NIRx, commented: “ “Artinis and NIRx have given me a very warm welcome, and I am truly impressed by the energy and commitment throughout both organizations. Together, we will build a strong and robust financial and IT foundation to support and enable the organization’s long-term growth plans.”
Boyd Rutten, Partner at Gilde Healthcare, commented: “Matthew and Maarten both bring valuable knowledge and a proven track record of success from their former leadership roles. They will play a key role in building a strong organization and further driving our growth strategy.”
About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €3.0 billion across three fund strategies: Venture&Growth, Private Equity and Climate Solutions. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Climate Solutions fund of Gilde Healthcare partners with companies that actively address planetary challenges linked to energy transition, biodiversity loss and waste & pollution. For more information, visit the company’s website at www.gildehealthcare.com.
